318 related articles for article (PubMed ID: 26598551)
1. Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition.
Kim M; Kim M; Park SJ; Lee C; Lim DS
EMBO Rep; 2016 Jan; 17(1):64-78. PubMed ID: 26598551
[TBL] [Abstract][Full Text] [Related]
2. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
Mana-Capelli S; McCollum D
J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
[TBL] [Abstract][Full Text] [Related]
3. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
4. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor.
Paramasivam M; Sarkeshik A; Yates JR; Fernandes MJ; McCollum D
Mol Biol Cell; 2011 Oct; 22(19):3725-33. PubMed ID: 21832154
[TBL] [Abstract][Full Text] [Related]
5. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
[TBL] [Abstract][Full Text] [Related]
6. Angiomotins link F-actin architecture to Hippo pathway signaling.
Mana-Capelli S; Paramasivam M; Dutta S; McCollum D
Mol Biol Cell; 2014 May; 25(10):1676-85. PubMed ID: 24648494
[TBL] [Abstract][Full Text] [Related]
7. Actin-binding and cell proliferation activities of angiomotin family members are regulated by Hippo pathway-mediated phosphorylation.
Chan SW; Lim CJ; Guo F; Tan I; Leung T; Hong W
J Biol Chem; 2013 Dec; 288(52):37296-307. PubMed ID: 24225952
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
9. Angiomotin'g YAP into the nucleus for cell proliferation and cancer development.
Hong W
Sci Signal; 2013 Sep; 6(291):pe27. PubMed ID: 24003252
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness.
Artinian N; Cloninger C; Holmes B; Benavides-Serrato A; Bashir T; Gera J
J Biol Chem; 2015 Aug; 290(32):19387-401. PubMed ID: 25998128
[TBL] [Abstract][Full Text] [Related]
11. Amot130 adapts atrophin-1 interacting protein 4 to inhibit yes-associated protein signaling and cell growth.
Adler JJ; Heller BL; Bringman LR; Ranahan WP; Cocklin RR; Goebl MG; Oh M; Lim HS; Ingham RJ; Wells CD
J Biol Chem; 2013 May; 288(21):15181-93. PubMed ID: 23564455
[TBL] [Abstract][Full Text] [Related]
12. AMOTL2 mono-ubiquitination by WWP1 promotes contact inhibition by facilitating LATS activation.
Hwang D; Kim M; Kim S; Kwon MR; Kang YS; Kim D; Kang HC; Lim DS
Life Sci Alliance; 2021 Oct; 4(10):. PubMed ID: 34404733
[TBL] [Abstract][Full Text] [Related]
13. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway.
Zeng H; Ortiz A; Shen PF; Cheng CJ; Lee YC; Yu G; Lin SC; Creighton CJ; Yu-Lee LY; Lin SH
Oncotarget; 2017 Feb; 8(6):10145-10160. PubMed ID: 28052036
[TBL] [Abstract][Full Text] [Related]
14. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein.
Zhao B; Li L; Lu Q; Wang LH; Liu CY; Lei Q; Guan KL
Genes Dev; 2011 Jan; 25(1):51-63. PubMed ID: 21205866
[TBL] [Abstract][Full Text] [Related]
15. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis.
Yi C; Shen Z; Stemmer-Rachamimov A; Dawany N; Troutman S; Showe LC; Liu Q; Shimono A; Sudol M; Holmgren L; Stanger BZ; Kissil JL
Sci Signal; 2013 Sep; 6(291):ra77. PubMed ID: 24003254
[TBL] [Abstract][Full Text] [Related]
16. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein.
DeRan M; Yang J; Shen CH; Peters EC; Fitamant J; Chan P; Hsieh M; Zhu S; Asara JM; Zheng B; Bardeesy N; Liu J; Wu X
Cell Rep; 2014 Oct; 9(2):495-503. PubMed ID: 25373897
[TBL] [Abstract][Full Text] [Related]
17. KIBRA regulates Hippo signaling activity via interactions with large tumor suppressor kinases.
Xiao L; Chen Y; Ji M; Dong J
J Biol Chem; 2011 Mar; 286(10):7788-7796. PubMed ID: 21233212
[TBL] [Abstract][Full Text] [Related]
18. Hippo pathway-independent restriction of TAZ and YAP by angiomotin.
Chan SW; Lim CJ; Chong YF; Pobbati AV; Huang C; Hong W
J Biol Chem; 2011 Mar; 286(9):7018-26. PubMed ID: 21224387
[TBL] [Abstract][Full Text] [Related]
19. cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes.
Kim M; Kim M; Lee S; Kuninaka S; Saya H; Lee H; Lee S; Lim DS
EMBO J; 2013 May; 32(11):1543-55. PubMed ID: 23644383
[TBL] [Abstract][Full Text] [Related]
20. Angiomotin Family Members: Oncogenes or Tumor Suppressors?
Lv M; Shen Y; Yang J; Li S; Wang B; Chen Z; Li P; Liu P; Yang J
Int J Biol Sci; 2017; 13(6):772-781. PubMed ID: 28656002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
